“Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension.” Irene Lang, Bernhard C. Meyer, Takeshi Ogo, Hiromi Matsubara, Marcin Kurzyna, Hossein-Ardeschir Ghofrani, Eckhard Mayer and Philippe Brenot. Eur Respir Rev 2017; 26: 160119. Source: Eur Respir Rev, 26 (144) 165119; 10.1183/16000617.5119-2016 Year: 2017
“Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis.” Yasuhiro Kondoh, Vincent Cottin and Kevin K. Brown. Eur Respir Rev 2017; 26: 170050. Source: Eur Respir Rev, 27 (148) 175050; 10.1183/16000617.5050-2017 Year: 2018
“Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis.” Bridget F. Collins and Ganesh Raghu. Eur Respir Rev 2019; 28: 190022. Source: Eur Respir Rev, 28 (154) 195022; 10.1183/16000617.5022-2019 Year: 2019
“Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension.” Irene M. Lang and Sean P. Gaine. Eur Respir Rev 2015; 24: 630–641. Source: Eur Respir Rev 2015; 25: 99 Year: 2016
“Metabolic dysfunction in pulmonary hypertension: from basic science to clinical practice.” Stephen Y. Chan and Lewis J. Rubin. Eur Respir Rev 2017; 26: 170094. Source: Eur Respir Rev, 27 (147) 175094; 10.1183/16000617.5094-2017 Year: 2018
“Triple therapy in idiopathic pulmonary fibrosis: an alarming press release.” A.U. Wells, J. Behr, U. Costabel, V. Cottin and V. Poletti. Eur Respir J 2012; 39: 805–806. Source: Eur Respir J 2012; 39: 1552 Year: 2012
“Exercise pulmonary haemodynamics: a test in search of purpose.” J. Gerry Coghlan and Harm Jan Bogaard. Eur Respir J 2016; 47: 1315–1317. Source: Eur Respir J 2016; 48: 285 Year: 2016
“Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis.” Vincent Cottin and Toby Maher. Eur Respir Rev 2015; 24: 58–64. Source: Eur Respir Rev 2015; 24: 545 Year: 2015
“Cardiovascular disease and COPD: dangerous liaisons?” Klaus F. Rabe, John R. Hurst and Samy Suissa. Eur Respir Rev 2018; 27: 180057. Source: Eur Respir Rev, 27 (150) 185057; 10.1183/16000617.5057-2018 Year: 2018
“Microalbuminuria as a potential novel cardiovascular biomarker in patients with COPD.” Ciro Casanova and Bartolome R. Celli. Eur Respir J 2014; 43: 951–953. Source: Eur Respir J 2014; 43: 1825 Year: 2014
“Is bronchiectasis really a disease?” Michal Shteinberg, Patrick A. Flume and James D. Chalmers. Eur Respir Rev 2020; 29: 190051. Source: Eur Respir Rev, 29 (155) 195051; 10.1183/16000617.5051-2019 Year: 2020
“RESPIRE: breathing new life into bronchiectasis.” Sanjay H. Chotirmall and James D. Chalmers. Eur Respir J 2018; 51: 1702444. Source: Eur Respir J, 51 (2) 1752444; 10.1183/13993003.52444-2017 Year: 2018
“The therapy of idiopathic pulmonary fibrosis: what is next?” Vivien Somogyi, Nazia Chaudhuri, Sebastiano Emanuele Torrisi, et al . Eur Respir Rev 2019; 28: 190021. Source: Eur Respir Rev, 28 (153) 195021; 10.1183/16000617.5021-2019 Year: 2019
“The patient tells it! The importance of patient's quality of life perception in pulmonary arterial hypertension risk assessment.” Silvia Ulrich and Ekkehard Grunig. Eur Respir J 2021; 57: 2004376 Source: Eur Respir J, 57 (3) 2054376; 10.1183/13993003.54376-2020 Year: 2021
“Haemoptysis due to pulmonary venous stenosis.” Silke Braun, Ivan Platzek, Klaus Zöphel, Matthias Weise, Martin Kolditz, Michael Halank and Gert Hoeffken. Eur Respir Rev 2014; 23: 170–179. Source: Eur Respir Rev 2014; 23: 399 Year: 2014
“Number needed to treat: enigmatic results for exacerbations in COPD.” Samy Suissa. Eur Respir J 2015; 45: 875–878. Source: Eur Respir J, 51 (6) 1452165; 10.1183/13993003.52165-2014 Year: 2018
“Health consequences associated with frequent wheezing in adolescents without asthma diagnosis.” K. Yeatts, K. Johnston Davis, D. Peden and C. Shy. Eur Respir J 2003; 22: 781–786. Source: Eur Respir J 2015; 46: 1532 Year: 2015
“Do bacteria have a role in asthma development?” J. Armann and E. von Mutius. Eur Respir J 2010; 36: 469–471. Source: Eur Respir J, 54 (1) 1050414; 10.1183/13993003.50414-2010 Year: 2019
“Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis.” Michael Kreuter, Marlies S. Wijsenbeek, Martina Vasakova, Paolo Spagnolo, Martin Kolb, Ulrich Costabel, Derek Weycker, Klaus-Uwe Kirchgaessler and Toby M. Maher. Eur Respir J 2016; 47: 1776–1784. Source: Eur Respir J 2016; 48: 593 Year: 2016
“Functional ageing in fibrotic interstitial lung disease: the impact of frailty on adverse health outcomes.” Sabina A. Guler, Joanne M. Kwan, Janice M. Leung, Nasreen Khalil, Pearce G. Wilcox and Christopher J. Ryerson. Eur Respir J 2020; 55: 1900647. Source: Eur Respir J, 55 (3) 1950647; 10.1183/13993003.50647-2019 Year: 2020